[P77] Poster Session 77　Lung Cancer/Thoracic Cancer（SCLC IO）

[P77-2] Phase 2 study of berzosertib（M6620）+ topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250

^○Tatsuya Yoshida¹, Anish Thomas², Federico Cappuzzo³, Cheng Ying⁴, Noboru Yamamoto¹, Yuanbin Chen⁵, Alexis B Cortot⁶, Thierry Berghmans⁷, NoemÍ Reguart⁸, Yuji Shibata⁹, Zhou Jianying¹⁰, Camilo Moulin¹¹, Barbara Sarholz¹², Jordi Ferrer-Playan¹¹, Anup Kalapur¹², Jayaprakasam Bolleddula¹³, Luis Paz-Ares¹⁴ (1.Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, 2.National Cancer Institute, Bethesda, MD, USA, 3.IRCCS Regina Elena National Cancer Institute, Rome, Italy, 4.Jilin Cancer Hospital, Changchun, China, 5.Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA, 6.Lille University Hospital, Lille, France, 7.Jules Bordet Institute, Brussels, Belgium, 8.Hospital Clinic, Barcelona, Spain, 9.National Cancer Center East Hospital, Chiba, Japan, 10.The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China, 11.Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, 12.Merck Healthcare KGaA, Darmstadt, Germany, 13.EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, 14.University Hospital 12 de Octubre, Madrid, Spain)